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Uromodulin has been associated with arterial hypertension in genome-wide association
studies, but data from clinical and preclinical studies are inconsistent. We here analyzed the
association of serum uromodulin (sUmod) with arterial hypertension and vasoactive hor-
mones in a population-based study.
Methods
In 1108 participants of the KORA F4 study aged 62–81 years, sUmod was measured and
the association of sUmod with arterial hypertension was assessed using logistic regression
models. The associations of sUmod with renin and aldosterone and with the vasoconstric-
tive prohormone C-terminal pro-endothelin-1 (CT-proET-1) were analyzed in 1079 partici-
pants and in 618 participants, respectively, using linear regression models.
Results
After multivariable adjustment including sex, age, eGFR, BMI, fasting glucose, current
smoking, previous stroke and myocardial infarction, sUmod was inversely associated with
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arterial hypertension (OR 0.78; 95% CI 0.68–0.91; p = 0.001). SUmod was not significantly
associated with renin and aldosterone after adjustment for sex, age and eGFR. However,
sUmod was inversely associated with CT-proET-1 (β -0.19 ± 0.04; p < 0.001) after adjust-
ment for sex, age, eGFR, BMI, arterial hypertension, fasting glucose, current smoking, pre-
vious stroke and myocardial infarction. The association with CT-proET-1 was stronger in
participants with hypertension (β -0.22 ± 0.04) than in normotensive participants (β -0.13 ±
0.06; p for interaction hypertension = 0.003 in the model adjusted for hypertension).
Conclusions
SUmod was inversely associated with arterial hypertension and the vasoconstrictive prohor-
mone CT-proET-1, suggesting direct or indirect effects of sUmod on blood pressure
regulation.
Introduction
Uromodulin is a glycosylphosphatidylinositol-anchored protein synthesized in tubular cells of
the ascending limb of Henle´s loop. The vast majority of uromodulin is released into the urine
by proteolytic cleavage [1–3]. Urinary uromodulin is crucial for renal integrity. Mutations of
the uromodulin-coding gene (UMOD) may cause severe kidney disease, such as cystic kidney
disease, recurring urinary tract infections, familial juvenile hyperuremic nephropathy and con-
genital nephrolithiasis [3–8]. A small proportion of uromodulin is actively secreted from the
basolateral side of tubular cells into the interstitial space and circulation (serum uromodulin,
sUmod) [9–11]. SUmod is considered to reflect intact tubular cells and thus indirectly neph-
ron mass [11]. In line, sUmod emerged as a promising marker for kidney function [10, 12, 13].
The physiological role of uromodulin in the systemic circulation is still unknown. However,
sUmod seems to play an important role beyond renal homeostasis, since it is inversely associ-
ated with all-cause and cardiovascular mortality [14–17] and with various cardiovascular risk
factors, such as diabetes [18, 19], the metabolic syndrome and its single components including
elevated blood pressure [20]. In contrast, genome-wide association studies [21–24] and animal
models [25, 26] show an increased risk of arterial hypertension in uromodulin-increasing
UMOD loci variants, and uromodulin has even been suggested to be a possible target for blood
pressure control [26]. Decreased luminal translocation of the Na+/K+/2Cl—co-transporter
(NKCC) in the thick ascending limb of Henle’s loop was proposed as a possible underlying
mechanism [27]. However, upregulation of renin and compensatory responses in distal and
proximal tubules were reported in an animal model as possible processes counteracting the
impaired NKCC translocation [27]. Thus, preclinical evidence suggests an interaction of uro-
modulin with the vasoregulatory renin-angiotensin-aldosterone system [27].
A further potent vasoconstrictor, endothelin-1 (ET-1), which is stimulated by aldosterone
in a negative feedback loop [28], also interferes with sodium and water uptake in the tubular
system and collecting ducts. The 21-amino acid peptide ET-1 is secreted by vascular endothe-
lium and by renal cells. The kidneys are both a source and a para- and autocrine target of ET-
1. The renal medulla contains the highest concentration of ET-1 in the body and the tubular
system may release more ET-1 than any other tissue [29]. ET-1 acts via different endothelin
receptors (ETR) and mediates vasoconstrictive effects by targeting endothelial cells and vascu-
lar smooth muscle cells via ETRA [30]. However, in the kidney, ET-1 predominantly binds to
ETRB, mediating natriuresis [31].
PLOS ONE Uromodulin and arterial hypertension
PLOS ONE | https://doi.org/10.1371/journal.pone.0237364 August 7, 2020 2 / 12
Funding: The study was supported by a research
grant from the Virtual Diabetes Institute (Helmholtz
Zentrum München) and the Clinical Cooperation
Group Diabetes, Ludwig-Maximilians-University
München and Helmholtz Zentrum München, and
by the German Diabetes Center. The German
Diabetes Center was supported by the Federal
Ministry of Health (Berlin, Germany) and the
Ministry of Culture and Science of the state North
Rhine Westphalia (Düsseldorf, Germany). The
KORA study was initiated and financed by the
Helmholtz Zentrum München - German Research
Center for Environmental Health, which is funded
by the German Federal Ministry of Education and
Research (BMBF) and by the State of Bavaria.
Further support was obtained from the Deutsche
Diabetes Gesellschaft (DDG) and from the German
Research Foundation (DFG, grant RA-45913/3-1).
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
The aim of the current study was to assess the association of sUmod with arterial hyperten-
sion in the population-based KORA F4 study. We further investigated the association of
sUmod with renin and aldosterone as well as with the prohormone C-terminal pro-endothe-
lin-1 (CT-proET-1), hypothesizing that these hormones are involved in an endocrine feedback
regulation of blood pressure. ET-1 is instable and rapidly cleared from the circulation, prevent-
ing reliable measurements. Therefore, we used CT-proET-1, which is cleaved from the respec-




The KORA (Cooperative Health Research in the Region of Augsburg) F4 study (2006–2008) is
a follow-up examination of the population-based KORA S4 study (1999–2001). Recruitment
and eligibility criteria for the KORA studies, study design, standardized sampling methods
and data collection (medical history, medication, anthropometric measurements, blood pres-
sure) have been described in detail previously [33–35]. The study was approved by the Ethics
Committees of the Bavarian Medical Association (approval number 06068) in adherence to
the declaration of Helsinki. All participants gave written informed consent before taking part.
SUmod was measured in 1119 participants aged 62–81 years of the KORA F4 study with avail-
able serum samples (out of a total of 1161 participants in this age group). All variables neces-
sary for the planned analyses were available in 1108 participants for the assessment of the
association of sUmod with arterial hypertension and in 1097 participants for the assessment of
the association of sUmod with renin/aldosterone. CT-proET-1 was measured in a subgroup
(n = 618) participating in the first half of the KORA F4 study. Blood pressure was measured
using a validated automatic device (OMRON HEM 705-CP). Three independent blood pres-
sure measurements were taken in a sitting position on the right arm after a rest of at least 5
minutes with a 3-minute pause between measurements. Arterial hypertension was defined
using the mean of the second and third blood pressure readings with a systolic blood
pressure� 140 mmHg and/or a diastolic blood pressure� 90 mmHg, and/or intake of anti-
hypertensive medication given that the participants were aware of having hypertension.
Laboratory measurements
Blood was collected without stasis in sitting position after a rest of 10 minutes (sitting) and
after an overnight fast of at least eight hours. Plasma and serum samples were assayed immedi-
ately or stored at -80˚C. Measurements of serum creatinine was performed with the Jaffe
method as described elsewhere [36]. Estimated glomerular filtration rate (eGFR) was calcu-
lated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
(2009) based on serum creatinine [37]. SUmod was measured with a commercially available
enzyme-linked immunosorbent assay kit (Euroimmun AG, Lübeck, Germany) with a lower
detection limit of 2 ng/ml, an intra-assay coefficient of variation of 2.3% and inter-assay coeffi-
cients of variation of 4.4% and 9.5% for sUmod target values of 24.9 and 142.2 ng/ml, respec-
tively. The measurement procedure was described by Steubl et al. [10]. Plasma concentrations
of C-terminal pro-endothelin-1 (CT-proET-1) were measured by sandwich fluoroimmunoas-
say (BRAHMS, Hennigsdorf/Berlin, Germany) using the automated system B.R.A.H.M.S
KRYPTOR as described previously [38]. The lower detection limit was 0.4 pmol/l. Plasma
renin concentrations were measured using the Liaison active renin assay (Diasorin, Dietzen-
bach, Germany) using monoclonal antibodies to only detect active renin molecules without
interference with pro-renin. Intra- and inter-assay coefficients of variation were below 5.6%
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and 12.2%, respectively, and the functional sensitivity was <2.0 μU/ml. Plasma aldosterone
concentrations were determined with an inhouse immunoflurometric assay as described pre-
viously [39]. Inter- and intra-assay coefficients of variation were 15.2% and 7.3% in low, and
8.0% and 4.4% in high concentrations, respectively.
Statistical analyses
The analyses were performed using the statistical environment R, version 3.6.3. Characteristics
of the study participants were compared between participants without and with arterial hyper-
tension using t-tests in case of normally distributed variables. Mann-Whitney U-tests were
performed for variables with skewed distributions. Chi-square tests were used to compare
binomial proportions. The associations of sUmod as independent variable with the outcomes
of interest were assessed in logistic regression models in case of categorical dependent variables
and in linear regression models in case of continuous dependent variables. Continuous vari-
ables were transformed to a Gaussian distribution by the probability integral transformation
followed by an inverse transform sampling and were used as in calculations per one standard
deviation. In logistic and linear regression analyses, the association of sUmod with the respec-
tive dependent variables was adjusted for covariates in 5 models (model 1: sex, age (which are
both related to hypertension and have been shown to be associated with sUmod [18]); model
2: model 1 plus eGFR (which was decreased in hypertensive participants and is strongly related
to sUmod [12]); model 3: model 2 plus BMI (which is associated with sUmod [20]), fasting
glucose (associated with sUmod [18]), current smoking, previous stroke and myocardial
infarction; model 4: model 3 plus arterial hypertension; model 5: model 4 plus use of beta-
blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists,
since these medications might influence the renin-aldosterone-angiotensin system). Model 1
and 2 were applied for all analyses, model 3 for the assessment of arterial hypertension, model
4 for CT-proET-1 and model 5 for renin and aldosterone as dependent variables. The models
are given in the tables for each observation. The level of statistical significance was set at 5%




Characteristics of the study population in total and stratified by arterial hypertension are
shown in Table 1. Values for eGFR were 7.5% and for sUmod 21.9% lower in participants with
arterial hypertension compared to normotensive participants. Renin and CT-proET-1 were
significantly higher in participants with hypertension, whereas aldosterone was similar in both
groups.
Association of sUmod with arterial hypertension
SUmod was inversely associated with arterial hypertension in the crude analysis (OR 0.61;
95% CI 0.54–0.70; Table 2). Stepwise adjustment revealed an attenuation of the association of
sUmod with arterial hypertension by correction for sex and age and eGFR. Adjustment for
BMI further attenuated the OR to 0.76 (95% CI 0.66–0.88), but including fasting glucose,
smoking, previous stroke and myocardial infarction into the model hardly affected the result,
and the association remained significant in the fully adjusted model (OR 0.78; 95% CI 0.68–
0.91; p = 0.001).
PLOS ONE Uromodulin and arterial hypertension
PLOS ONE | https://doi.org/10.1371/journal.pone.0237364 August 7, 2020 4 / 12
Lacking association of sUmod with renin and aldosterone
In the crude analysis, sUmod was inversely related to renin in the total study group (β -0.14 ±
0.03; p< 0.001) and in participants with arterial hypertension (β -0.13 ± 0.04; p = 0.002).
These associations were attenuated after adjustment for sex and age and lost significance after
further adjustment for eGFR (Table 3). In a sensitivity analysis, we found an inverse associa-
tion of renin with eGFR (β -0.18 ± 0.03; p< 0.001), which was stronger than the inverse associ-
ation with sUmod, and a positive association of renin with male sex (β 0.41 ± 0.06; p< 0.001).
There was no significant association of renin with age (β 0.05 ± 0.03; p = 0.12). The multivari-
able linear regression model including eGFR, sex and sUmod revealed a robust association of
renin with eGFR (β -0.17 ± 0.03; p< 0.001) and with male sex (β 0.41 ± 0.06; p< 0.001),
Table 1. Characteristics of study participantsa.
All participants Participants without hypertension Participants with hypertension p b
n 1108 414 694
Female sex n (%) 546 (49) 230 (56) 316 (46) < 0.001 ###
Age (years) 70.4 ± 5.5 69.0 ± 5.2 71.1 ± 5.5 < 0.001 #
BMI (kg/m2) 28.7 ± 4.5 27.3 ± 4.0 29.6 ± 4.6 < 0.001 #
Systolic blood pressure (mmHg) 128.5 ± 19.6 119.8 ± 13.8 133.7 ± 20.8 < 0.001 #
Diastolic blood pressure (mmHg) 74.0 ± 10.0 71.8 ± 8.3 75.4 ± 10.7 < 0.001 #
eGFR (ml/min/1.73 m2) 77.9 (67.3; 87.8) 81.4 (72.0; 89.7) 75.3 (64.2; 85.5) < 0.001 ##
sUmod (ng/ml) 152.5 (110.1; 207.7) 176.9 (126.5; 228.4) 138.1 (99.2; 190.4) < 0.001 ##
Previous stroke n (%) 46 (4) 5 (1) 41 (6) 0.21 ###
Previous myocardial infarction n (%) 65 (6) 16 (4) 49 (7) < 0.001 ###
Current smoking n (%) 81 (7) 41 (10) 40 (6) 0.03 ###
n 1097 409 688
Renin (ng/l) 11.0 (5.3; 22.4) 8.8 (5.1; 15.6) 12.8 (5.4; 30.9) < 0.001 ##
Aldosterone (ng/l) 37.2 (24.0; 56.0) 38.0 (24.0; 56.0) 36.0 (25.2; 54.0) 0.81 ##
n 618 220 398
CT-proET-1 (pmol/l) 51.5 (44.6; 61.2) 47.6 (42.8; 54.3) 53.8 (46.5; 64.3) < 0.001 ##
a Mean ± standard deviation, median (first quartile; third quartile), or number of participants (proportion in %)





Table 2. Odds ratios (95% confidence interval) for arterial hypertension as dependent variable and sUmod as
independent variable (per standard deviation).
Without adjustment P value
0.61 (0.54; 0.70) < 0.001
Model 1: Adjustment for sex and age
0.66 (0.58; 0.76) < 0.001
Model 2: Adjustment for sex, age and eGFR
0.70 (0.61; 0.81) < 0.001
Model 3: Adjustment for sex, age, eGFR, BMI, fasting glucose, smoking, previous stroke and myocardial infarction
0.78 (0.68; 0.91) 0.001
Results of logistic regression models. n = 1108.
https://doi.org/10.1371/journal.pone.0237364.t002
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whereas the association with sUmod was attenuated to non-significance (β -0.04 ± 0.03;
p = 0.18), indicating that the association of renin with sUmod was not independent of sex and
eGFR. There was no significant association of sUmod with aldosterone in any model
(Table 3).
Association of sUmod with CT-proET-1
SUmod was inversely associated with CT-proET-1 (Table 4). The association was more pro-
nounced in participants with arterial hypertension (β -0.44 ± 0.05; p< 0.001) compared to
participants without hypertension (β -0.21 ± 0.06; p< 0.001). Adjustment for sex and age only
moderately attenuated these associations, whereas further adjustment for eGFR had a stronger
impact on the observed β-coefficients in participants with hypertension. Nevertheless, the
association of sUmod with CT-proET-1 remained significant in the fully adjusted model in
participants with arterial hypertension (β -0.22 ± 0.04; p< 0.001) and in normotensive partici-
pants (β -0.13 ± 0.06; p = 0.023). Throughout the models, the association of sUmod with CT-
proET-1 was stronger in hypertensive than in normotensive participants. The p value for inter-
action hypertension was 0.003 in a model adjusted for hypertension only, and 0.078 in the
fully adjusted model.
Discussion
The current data demonstrates an inverse association of sUmod with arterial hypertension in a
large population-based study. This finding strengthens the view that uromodulin mirrors a
vaso- and nephroprotective mediator molecule. Our data are in line with previous clinical
studies involving participants at high cardiovascular risk or with cirrhosis, which reported a
lower prevalence of arterial hypertension in participants with higher serum or plasma uromo-
dulin values [13, 14, 16, 40]. These findings are in contrast with the results of genome-wide
Table 3. Association estimates between sUmod and renin and aldosterone.
Renin P value Aldosterone P value
Without adjustment
Total study group -0.14 ± 0.03 < 0.001 0.01 ± 0.10 0.857
No arterial hypertension -0.08 ± 0.04 0.072 0.05 ± 0.05 0.332
Arterial hypertension -0.13 ± 0.04 0.002 -0.02 ± 0.04 0.547
Model 1: Adjustment for sex and age
Total study group -0.10 ± 0.03 0.001 -0.02 ± 0.03 0.498
No arterial hypertension -0.05 ± 0.04 0.261 0.04 ± 0.05 0.476
Arterial hypertension -0.01 ± 0.04 0.024 -0.05 ± 0.04 0.176
Model 2: Adjustment for sex, age and eGFR
Total study group -0.05 ± 0.03 0.088 0.01 ± 0.03 0.699
No arterial hypertension -0.04 ± 0.04 0.355 0.05 ± 0.05 0.375
Arterial hypertension -0.04 ± 0.04 0.403 -0.01 ± 0.04 0.713
Model 5: Adjustment for sex, age, eGFR, BMI, fasting glucose, smoking, previous stroke and myocardial infarction, use of beta-blockers, angiotensin-converting
enzyme inhibitors and angiotensin receptor antagonists (and arterial hypertension in the total study group)
Total study group 0.02 ± 0.04 0.566 -0.02 ± 0.04 0.695
No arterial hypertension -0.01 ± 0.04 0.895 0.08 ± 0.06 0.135
Arterial hypertension 0.01 ± 0.03 0.777 0.02 ± 0.04 0.456
β coefficient ± standard error from linear regression models are given per standard deviation sUmod. n = 1097 (total study group), 409 (without arterial hypertension),
688 (with arterial hypertension).
https://doi.org/10.1371/journal.pone.0237364.t003
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association and preclinical studies. Single nucleotid polymorphisms in the UMOD promoter
region increasing uromodulin levels are associated with hypertension [21–23, 41], and the
UMOD rs13333226 minor G allele interrelates with a reduced urinary uromodulin excretion
and a decreased risk of arterial hypertension [21]. In transgenic mice, UMOD overexpression
correlates positively with blood pressure [26], and lower systolic blood pressure and resistance
to salt-induced blood pressure changes were reported in UMOD -/- mice [25]. Liu et al. con-
firmed salt and water wasting in young UMOD -/- mice and identified an impaired luminal
translocation of the NKCC-transporter in the thick ascending limb of Henle’s loop as probable
underlying mechanism [27]. However, Liu et al. also showed an age-dependency of the
UMOD knockout effect on arterial hypertension with oliguria and hypertension in aged
UMOD -/- mice, possibly due to a marked upregulation of renin and compensatory responses
in distal and proximal tubules [27]. In line, UMOD -/- mice in another study showed an upre-
gulation of major distal ion transporters including Na+/K+-ATPase, NKCC2, chloride channel
protein class K2, Na+/Cl- channel and epithelial sodium channel [42]. In a further mouse
model, genetic deletion of UMOD was reflected by a shift of Na+/Cl− cotransporter activity
from the early part of the distal convoluted tubule to the downstream segment [43]. Further,
despite its relation to a decreased risk for arterial hypertension, the uromodulin-lowering
UMOD rs13333226 G allele is associated with a lower fractional sodium excretion during lib-
eral sodium intake [21], indicating an increased sodium reabsorption at the proximal tubular
level in conditions of reduced uromodulin.
Aside from genetic variations, under physiological conditions, uromodulin possibly regu-
lates blood pressure via interference with the tubular electrolyte and water transport [25, 26,
44]. Due to the glycosylphosphatidylinositol-anchor, urinary uromodulin can form a highly
ordered organization constituting a physical water barrier on the luminal membrane of the
Table 4. Association estimates between sUmod and CT-proET-1.
CT-proET-1 P value
Without adjustment
Total study group -0.39 ± 0.04 < 0.001
No arterial hypertension -0.20 ± 0.06 0.001
Arterial hypertension -0.44 ± 0.05 < 0.001
P value for interaction hypertension 0.003
Model 1: Adjustment for sex and age
Total study group -0.34 ± 0.04 < 0.001
No arterial hypertension -0.15 ± 0.06 0.014
Arterial hypertension -0.40 ± 0.05 < 0.001
Model 2: Adjustment for sex, age and eGFR
Total study group -0.25 ± 0.03 < 0.001
No arterial hypertension -0.16 ± 0.06 0.008
Arterial hypertension -0.28 ± 0.04 < 0.001
Model 4: Adjustment for sex, age, eGFR, BMI, fasting glucose, smoking, previous stroke and myocardial infarction
(and arterial hypertension in the total cohort)
Total study group -0.19 ± 0.04 < 0.001
No arterial hypertension -0.13 ± 0.06 0.023
Arterial hypertension -0.22 ± 0.04 < 0.001
P value for interaction hypertension 0.078
β coefficient ± standard error from linear regression models are given per standard deviation sUmod. n = 618 (total
study group), 220 (without arterial hypertension), 398 (with arterial hypertension).
https://doi.org/10.1371/journal.pone.0237364.t004
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epithelial cells of the thick ascending limb of Henle’s loop, thereby reducing water and salt
reabsorption [44]. In line, a large study including more than 6500 participants found a positive
relation of urinary uromodulin with sodium, chloride and potassium excretion [45]. Assuming
uromodulin regulates blood pressure by decreasing the Na+/K+/Cl—reabsorption, low blood
pressure should be associated with an activation of the renin-angiotensin-aldosterone system
in conditions of low uromodulin. In our study, sUmod was inversely associated with renin,
but this effect lost significance after multivariable adjustment. Further, there was no associa-
tion with aldosterone levels. A possible explanation for the lack of an association of uromodu-
lin with renin/aldosterone may be an interference of urinary uromodulin with the
tubuloglomerular feedback via interaction with the NKCC2 at the macula densa under physio-
logical conditions. Also, standard anti-hypertensive medication interfering with the renin-
angiotensin-aldosterone system may have obscured the association in participants with
hypertension.
SUmod was inversely associated with the vasoconstrictive prohormone CT-proET-1 in the
current study. CT-proET-1 has been previously associated with renal function [46]. However,
the association of sUmod with CT-proET-1 was largely independent of the eGFR. In the kid-
ney, ET-1 also interferes with natriuresis. Binding of ET-1 to ETRB inhibits NKCC activity in
rats [31, 47]. Whether uromodulin and ET-1 directly interact in the kidneys to modulate elec-
trolyte and water transport is not known. The effect of ETRB depends on calcium influx, as
shown in cultured renal inner medullary cells [48]. Uromodulin has recently been shown to
influence calcium flux as it upregulates TRPV5 and TRPM6 and thus stimulates calcium and
magnesium reabsorption [49, 50].
In our study, we measured uromodulin and CT-proET-1 in serum. In the urinary tract,
uromodulin binds various components including leukocytes, fimbriated bacteria and calcium
phosphate crystals [3]. It is not yet clarified whether sUmod has similar properties in the circu-
lation and can bind, modulate, neutralize or eliminate serum components, including CT-
proET-1, as well.
The relation of sUmod with CT-proET-1 was present in participants with or without arte-
rial hypertension, but the effect was significantly stronger in hypertensive participants, indicat-
ing that a feed-back mechanism may exist in arterial hypertension to limit the action of the
vasoconstrictive prohormone CT-proET-1. On the other hand, a decrease of sUmod secretion
by paracrine actions of CT-proET-1 in the tubular system is also conceivable. Little is known
about the regulation of uromodulin secretion into the circulation and mechanistic studies
exploring the nature of the interaction of sUmod and vasoconstrictive hormones are lacking.
Study limitations and strengths
Only participants aged� 62 years were included. Thus, the association of sUmod with arterial
hypertension and vasoactive hormones remains to be confirmed in a younger population. We
only had measurements of uromodulin and CT-proET-1 in serum and cannot answer the
question whether serum levels accurately reflect urine levels. In fact, uromodulin values in
serum and in urine appear to correlate only moderately and their association with clinical
characteristics may differ [51, 52]. Due to the observational nature of the study, we are not able
to provide mechanistic links and causal relationships for our observations and reverse causa-
tion cannot be excluded. It is conceivable that hypertension-related microvascular injury may
impair tubular function and thus decrease uromodulin secretion. Further, the impact of
genetic polymorphisms on sUmod concentrations was not investigated in the current study.
However, our analyses were done in a large, well characterized community-based study group.
We measured sUmod with a sensitive and robust enzyme-linked immunosorbent assay. In
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contrast to uromodulin of urine origin, which forms various polymers with chancing epitopes
and different antigenic sites [53], sUmod is a stable antigen without such pre-analytical disad-
vantages [9]. To our knowledge, the association of sUmod with the vasoconstrictive prohor-
mone CT-proET-1 has not been analyzed before and the relation of sUmod with renin and
aldosterone was not yet examined in humans.
Conclusions
We demonstrate an inverse association of sUmod with arterial hypertension and with the
vasoconstrictive prohormone CT-proET-1 in the population-based KORA F4 study. Thus, we
provide indirect evidence for a systemic blood pressure regulative effect of sUmod. Further
studies are required to clarify the mechanistic links between sUmod, arterial hypertension and
ET-1.
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35. Meisinger C, Rückert IM, Rathmann W, Döring A, Thorand B, Huth C, et al. Retinol-binding protein 4 is
associated with prediabetes in adults from the general population: The cooperative health research in
the Region of Augsburg (KORA) F4 study. Diabetes Care. 2011; 34: 1648–1650. https://doi.org/10.
2337/dc11-0118 PMID: 21617096
36. Seissler J, Feghelm N, Then C, Meisinger C, Herder C, Koenig W, et al. Vasoregulatory peptides pro-
endothelin-1 and pro-adrenomedullin are associated with metabolic syndrome in the population-based
KORA F4 study. Eur J Endocrinol. 2012; 167: 847–853. https://doi.org/10.1530/EJE-12-0472 PMID:
23002189
37. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate
glomerular filtration rate. Ann Intern Med. 2009; 150: 604–612. https://doi.org/10.7326/0003-4819-150-
9-200905050-00006 PMID: 19414839
38. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable
peptide derived from the precursor of vasopressin. Clin Chem. 2006; 52: 112–119. https://doi.org/10.
1373/clinchem.2005.060038 PMID: 16269513
39. Manolopoulou J, Bielohuby M, Caton SJ, Gomez-Sanchez CE, Renner-Mueller I, Wolf E, et al. A highly
sensitive immunofluorometric assay for the measurement of aldosterone in small sample volumes: Vali-
dation in mouse serum. J Endocrinol. 2008; 196: 215–224. https://doi.org/10.1677/JOE-07-0134 PMID:
18252945
40. Patidar KR, Garimella PS, Macedo E, Slaven JE, Ghabril MS, Weber RE, et al. Admission plasma uro-
modulin and the risk of acute kidney injury in hospitalized patients with cirrhosis: a pilot study. Am J Phy-
siol Gastrointest Liver Physiol. 2019; 317: G447–G452. https://doi.org/10.1152/ajpgi.00158.2019
PMID: 31411505
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